Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at ...
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually from June 4-8, 2021.
“We are very pleased to report that research involving seclidemstat will be the subject of three poster presentations at the 2021 ASCO Annual Meeting,” stated David Arthur, President and CEO of Salarius Pharmaceuticals. “As previously noted, the full findings from the dose escalation-stage of the Phase 1/2 trial of seclidemstat in patients with relapsed and refractory Ewing sarcoma, including details on safety, dosing, and initial efficacy signal, and preliminary data from the solid tumor trial including FET-translocated sarcomas, also known as Ewing-related sarcomas, will be reported at the conference.”
This year, ASCO received and reviewed more than 5,400 abstracts for the 2021 ASCO Annual Meeting. Information about the meeting may be accessed via the following website: https://meetings.asco.org/am/registration. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 19, 2021.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for the Ewing sarcoma program. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “anticipate,” “potential,” “progress,” “design,” “estimate,” “continue,” “will,” “aim,” “can,” “believe,” “plan,” “allow,” “expect,” “intend,” “goal,” “provide,” “able to,” “
Johanna Bennett (media relations)